Patents by Inventor Heung Mo Kang

Heung Mo Kang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220380304
    Abstract: The present invention relates to a method for producing peramivir trihydrate, which is an inhibitor of neuraminidase infection, as an anti-influenza agent. According to the production method of the present invention, peramivir trihydrate can be produced with high yield and stability through a process suitable for producing excellent pharmaceuticals and quality control standards (GMP) without using highly-toxic methanol and activated carbon.
    Type: Application
    Filed: July 2, 2020
    Publication date: December 1, 2022
    Inventors: Hee Un KIM, In Kyu KIM, Myeong Seok LEE, Heung Mo KANG, Sae Jin KIM, In Suk CHOI
  • Patent number: 9018349
    Abstract: The present invention relates to a novel process for preparing the aza cyclohexapeptide compound 1-[(4R,5S)-5-[(2-aminoethyl)amino]-N2-(10,12-dimethyl-1-oxotetradecyl)-4-hydroxy-L-ornithine]-5-[(3R)-3-hydroxy-L-ornithine]-pneumocandin B0 (caspofungin) represented by the following formula 1, which can improve the problem due to a pungent odor and toxicity during the process and can prepare caspofungin as a final product at high yield compared to conventional processes, and to novel intermediates which are used in the preparation process:
    Type: Grant
    Filed: January 12, 2011
    Date of Patent: April 28, 2015
    Assignee: CKD Bio Corp.
    Inventors: Heui-Il Kang, Yun-Beom Ham, Su-Hyun Kyong, Heung-Mo Kang, Tae-Hee Han, Doo-Jin Kang
  • Publication number: 20130261286
    Abstract: The present invention relates to a novel process for preparing the aza cyclohexapeptide compound 1-[(4R,5S)-5-[(2-aminoethyl)amino]-N2-(10,12-dimethyl-1-oxotetradecyl)-4-hydroxy-L-ornithine]-5-[(3R)-3-hydroxy-L-ornithine]-pneumocandin B0 (caspofungin) represented by the following formula 1, which can improve the problem due to a pungent odor and toxicity during the process and can prepare caspofungin as a final product at high yield compared to conventional processes, and to novel intermediates which are used in the preparation process:
    Type: Application
    Filed: January 12, 2011
    Publication date: October 3, 2013
    Applicant: CKD BIO CORP.
    Inventors: Heui-Il Kang, Yun-Beom Ham, Su-Hyun Kyong, Heung-Mo Kang, Tae-Hee Han, Doo-Jin Kang
  • Patent number: 8334277
    Abstract: The present invention relates to a novel {4-[2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenoxy}phosphate or a pharmaceutically acceptable salt thereof, a production method therefor and a pharmaceutical composition for preventing and treating central nervous system disorders which contains the same as an active component. The novel {4-[2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenoxy}phosphate or a pharmaceutically acceptable salt thereof according to the present invention can beneficially be used to prevent and treat central nervous system disorders since it exhibits an equivalent biological and pharmacological activity to venlafaxine and salts thereof which are known in the field, it has very little toxicity, and, in particular, it is outstandingly soluble in water as compared with prior-art venlafaxine derivatives.
    Type: Grant
    Filed: May 8, 2009
    Date of Patent: December 18, 2012
    Assignee: JE IL Pharmaceutical Co., Ltd.
    Inventors: Seok Won Kang, Jong Soo Chun, Heung Mo Kang, Eui Seok Hong, Kwang-Woo Chun, Young Seok Byun, Myung-Hwa Kim, Young Il Moon, Jei Man Ryu
  • Publication number: 20110059923
    Abstract: The present invention relates to a novel {4-[2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenoxy}phosphate or a pharmaceutically acceptable salt thereof, a production method therefor and a pharmaceutical composition for preventing and treating central nervous system disorders which contains the same as an active component. The novel {4-[2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenoxy}phosphate or a pharmaceutically acceptable salt thereof according to the present invention can beneficially be used to prevent and treat central nervous system disorders since it exhibits an equivalent biological and pharmacological activity to venlafaxine and salts thereof which are known in the field, it has very little toxicity, and, in particular, it is outstandingly soluble in water as compared with prior-art venlafaxine derivatives.
    Type: Application
    Filed: May 8, 2009
    Publication date: March 10, 2011
    Applicant: JE IL PHARMACEUTICAL CO., LTD.
    Inventors: Seok Won Kang, Jong Soo Chun, Heung Mo Kang, Eui Seok Hong, Kwang-Woo Chun, Young Seok Byun, Myung-Hwa Kim, Young II Moon, Jei Man Ryu